

1 **Molecular basis of diseases caused by the mtDNA mutation**
2 **m.8969G>A in the subunit *a* of ATP synthase**

3 Natalia Skoczeń^{1,2§}, Alain Dautant^{2,3§}, Krystyna Binko^{1,2}, François Godard^{2,3}, Marine
4 Bouhier^{2,3}, Xin Su^{4,5}, Jean-Paul Lasserre^{2,3}, Marie-France Giraud^{2,3}, Déborah
5 Tribouillard-Tanvier^{2,3£}, Huimei Chen⁴, Jean-Paul di Rago^{2,3*}, Roza Kucharczyk^{1*}

6 ¹Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

7 ²CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33077 Bordeaux,
8 France

9 ³Université de Bordeaux, IBGC, UMR 5095, F-33077 Bordeaux, France

10 ⁴Nanjing University School of Medicine, Nanjing, Jiangsu, China

11 ⁵Center of Drug Discovery, State Key Laboratory of Natural Medicines, China
12 Pharmaceutical University, Nanjing, Jiangsu, China

13 [£]Research Associate from INSERM

14
15 [§]These authors equally contributed

16
17 *Corresponding authors: roza@ibb.waw.pl or jp.dirago@ibgc.cnrs.fr

18
19

20 **Abstract**

21

22 The ATP synthase which provides aerobic eukaryotes with ATP, organizes into a
23 membrane-extrinsic catalytic domain, where ATP is generated, and a membrane-
24 embedded F_O domain that shuttles protons across the membrane. We previously
25 identified a mutation in the mitochondrial *MT-ATP6* gene (m.8969G>A) in a 14-year-
26 old Chinese female who developed an isolated nephropathy followed by brain and
27 muscle problems. This mutation replaces a highly conserved serine residue into
28 asparagine at amino acid position 148 of the membrane-embedded subunit *a* of ATP
29 synthase. We showed that an equivalent of this mutation in yeast (*aS₁₇₅N*) prevents
30 F_O -mediated proton translocation. Herein we identified four first-site intragenic
31 suppressors (*aN₁₇₅D*, *aN₁₇₅K*, *aN₁₇₅I*, and *aN₁₇₅T*), which, in light of a recently
32 published atomic structure of yeast F_O , indicating that the detrimental consequences
33 of the original mutation result from the establishment of hydrogen bonds between
34 *aN₁₇₅* and a nearby glutamate residue (*aE₁₇₂*) that was proposed to be critical for the
35 exit of protons from the ATP synthase towards the mitochondrial matrix. Interestingly
36 also, we found that the *aS₁₇₅N* mutation can be suppressed by second-site
37 suppressors (*aP₁₂S*, *aI₁₇₁F*, *aI₁₇₁N*, *aI₂₃₉F*, and *aI₂₀₀M*), of which some are very
38 distantly located (by 20-30 Å) from the original mutation. The possibility to
39 compensate through long-range effects the *aS₁₇₅N* mutation is an interesting
40 observation that holds promise for the development of therapeutic molecules.

41

42

43

44 **Keywords:** ATP synthase, subunit *a*, mtDNA, *MT-ATP6*, oxidative phosphorylation,
45 metabolic disease

46

47 **1. Introduction**

48 The ATP synthase is found in the inner mitochondrial membrane and catalyzes the
49 last step in oxidative phosphorylation (OXPHOS) by producing ATP from ADP and
50 inorganic phosphate using the transmembrane proton gradient, also called the
51 proton-motive force (*pmf*), generated during the transfer of electrons to oxygen by the
52 respiratory chain (RC) complexes (I–IV) [1]. Cryo-EM structures of the bovine *Bos*
53 *taurus* and yeasts *Yarrowia lipolytica* and *Saccharomyces cerevisiae* F₁F₀ ATP
54 synthases, that are basically of the same subunit composition and structural
55 construction as the human enzyme, have been described recently [2-5]. The ATP
56 synthase organizes into a membrane-extrinsic F₁ catalytic and a membrane-
57 embedded F₀ domain that are connected by a peripheral and central stalk [4, 6]. ATP
58 synthase exists as dimers [2, 6] that assemble into long ribbons important for cristae
59 formation [7, 8], which is crucial with respect to accommodation within the
60 mitochondrial inner membrane of the OXPHOS respiratory chain complexes and the
61 ATP synthase in most efficient and native way.

62 Within the F₀, protons are shuttled across the membrane by subunit *a* and a
63 ring of identical subunits *c* (8 in mammals, 10 in yeast). Hydrophilic amino acids of
64 subunit *a* allow protons to enter the F₀ from the IMS. Approximately in the middle of
65 the membrane the proton can bind to a highly conserved acidic residue of subunit *c*
66 helix 2 (*cH2*) (*cE₅₉* in *H. sapiens*) located at the outer surface of the *c*-ring. The
67 binding of a proton on this carboxylate residue disrupts a previously established
68 electrostatic interaction of *cE₅₉* with a highly conserved positively charged arginine
69 residue in subunit *a* membrane helix 5 (*aH5*) (*aR₁₅₉* in *H. sapiens*) [5, 9, 10]. This
70 arginine acts as an electrostatic separator between the proton pathway from the IMS
71 to the middle of the membrane and a second, spatially separated pathway that allow

72 incoming protons still bound on the *c*-ring glutamate to be released into the matrix
73 [11]. The operation direction of this process is primarily driven by the ion gradient that
74 causes a ratchet type mechanism of the neutralized *c*-ring glutamate in the
75 hydrophobic membrane, which does energetically not allow the back stepping without
76 externally applied force [9, 10]. After an almost complete revolution of the *c*-ring, the
77 glutamate is deprotonated in the aqueous exit channel [12] and the proton is moved
78 towards the mitochondrial matrix [2, 4-6, 13]. The *c*-ring is tightly bound to the central
79 stalk, a three subunit subcomplex of F_1 ($\gamma\delta\epsilon$), which induces upon rotation cyclic
80 conformational changes in the $(\alpha\beta)_3$ catalytic head of F_1 that favor synthesis and
81 release of ATP [14], according to the binding change mechanism [1].

82 Devastating human neuromuscular disorders (e.g. Neuropathy, Ataxia, and
83 Retinitis Pigmentosa (NARP) and Maternally Inherited Leigh Syndrome (MILS)) have
84 been associated to numerous mutations in subunit *a* [15]. This protein is encoded by
85 the mitochondrial *MT-ATP6* gene. Human cells contain up to thousands copies of
86 mtDNA [16]. Mutations in this DNA are highly recessive and usually co-exist in
87 patient's cells and tissues with wild type mtDNA molecules, a situation referred to as
88 heteroplasmy. These features make it difficult to precisely know how specific
89 pathogenic mtDNA mutations influence oxidative phosphorylation. To better
90 characterize the effects of disease-causing subunit *a* mutations, we exploited unique
91 features of *Saccharomyces cerevisiae*. Mitochondria from this single-celled fungus
92 and humans show many similarities [17-21], and mitochondrial genetic transformation
93 can be achieved in this yeast in a highly controlled fashion, by the biolistic delivery
94 into mitochondria of in-vitro-made mutated mtDNA fragments, followed by their
95 integration into wild type mtDNA by homologous DNA recombination [22]. Being
96 unable to stably maintain heteroplasmy [23], it is easy to obtain yeast homoplasmic

97 populations where all mtDNA molecules carry a mutation of interest. Owing to its
98 good fermenting capacity, yeast models of human mitochondrial diseases can be
99 kept alive when provided with sugars like glucose even when oxidative
100 phosphorylation is completely inactivated [24, 25].

101 We used this yeast-based approach to investigate the impact on ATP
102 synthase of nine subunit *a* missense mutations identified in patients [15, 25-33].
103 Some of these mutations were found to compromise incorporation of subunit *a* into
104 ATP synthase, whereas others prevent the functioning of F_0 without minor or any
105 assembly defect. While these observations are interesting, it is often difficult to
106 understand why the mutations are detrimental. Further information may be obtained
107 by the isolation of intragenic suppressor mutations. In doing so, it is possible to
108 identify novel amino acids at the original mutation site that are compatible with
109 subunit *a* function as well as second-site suppressors that make the primary mutation
110 no longer or less detrimental.

111 We here applied this suppressor genetics approach to a mutation in subunit *a*
112 (m.8969G>A, *aS*₁₄₈N) that we previously identified in a 14-year-old Chinese female
113 who initially developed an isolated nephropathy followed by a complex clinical
114 presentation with brain and muscle problems [33]. With an equivalent of this mutation
115 (*aS*₁₇₅N), yeast fails to grow on non-fermentable carbon sources due to a lack of F_0 -
116 mediated proton transfer [33]. The isolation of respiratory sufficient revertants from
117 the mutant *aS*₁₇₅N led us to identify four first-site (*aN*₁₇₅D, *aN*₁₇₅K, *aN*₁₇₅I, and *aN*₁₇₅T)
118 and five second-site (*aP*₁₂S, *aI*₁₇₁F, *aI*₁₇₁N, *aI*₂₃₉F, and *aI*₂₀₀M) suppressor mutations
119 restoring to varying degree ATP synthase function. The results, in the light of a
120 recently published atomic structure of yeast F_0 [5, 34], indicate that the detrimental
121 consequences of the *aS*₁₇₅N mutation may result from the establishment of hydrogen

122 bonds between αN_{175} and αE_{172} , a residue that was proposed to be critical for the exit
123 of protons from ATP synthase towards the mitochondrial matrix [5].

124

125

126

127

128 **2. Materials and Methods**

129 2.1. Growth media and genotypes

130 The media used for growing yeast were: YPGA (1% Bacto yeast extract, 1% Bacto
131 Peptone, 2% or 10% glucose, 40 mg/L adenine), YPGaIA (1% Bacto yeast extract,
132 1% Bacto Peptone, 2% galactose, 40 mg/L adenine), YPEGA (1% Bacto yeast
133 extract, 1% Bacto Peptone, 3% ethanol, 2% glycerol, 40 mg/L adenine), W0 (2%
134 glucose, 0.67% Nitrogen base with ammonium sulfate from Difco). SP1: 0.1%
135 glucose, 0.25% yeast extract, 50 mM potassium acetate. Solid media were obtained
136 by adding 2% Bacto Agar (Difco, Becton Dickinson). The genotypes of the strains
137 used in this study are listed in Table 1. Growth curves were established with the
138 Bioscreen CTM system.

139 2.2. Selection of respiratory-sufficient revertants from the yeast aS₁₇₅N mutant

140 The aS₁₇₅N mutant (strain RKY105) was subcloned on rich 2% glucose plates. Forty
141 single colonies were picked up and individually grown in 10% glucose. Glucose was
142 removed from the cultures by two washings with water and 10⁸ cells from each
143 culture were spread on rich glycerol/ethanol (YPEGA) plates. The plates were
144 incubated at 28°C for 25 days. Maximum 3 revertants per plate were retained for
145 further analysis. The revertants were purified by subcloning on glucose plates. They
146 were crossed on W0 minimal medium to strain D273-10B/60 devoid of mtDNA (ρ^0),
147 and the diploid cells were tested for their ability to grow on glycerol. The *ATP6* gene
148 was amplified by PCR with primers oATP6-1
149 5'TAATATACGGGGTGGGTCCCTCAC and oATP6-10
150 5'GGGCCGAAGTCCGAAGGAGTAAG, and sequenced entirely.

151

152 2.3. Bioenergetics analyses

153 Mitochondrial enzyme assays and membrane potential analyses were performed on
154 mitochondria isolated from yeast cells grown in rich galactose (YPGalA) at 28°C.
155 Mitochondria were prepared by the enzymatic method, as described [35]. Oxygen
156 consumption rates were measured with a Clark electrode in 0.65 M mannitol, 0.36
157 mM EGTA, 5 mM Tris/phosphate, 10 mM Tris/maleate pH 6.8 (respiration buffer), as
158 described [36]. For ATP synthesis rate measurements, the mitochondria (0.15 mg/ml)
159 were placed in a 1 ml thermostatically controlled chamber at 28°C in respiration
160 buffer. The reaction was started by adding 4 mM NADH and 750 μ M ADP; 100 μ l
161 aliquots were taken every 15 seconds (30 seconds for strains with a slow oxygen
162 consumption rate) and the reaction was stopped by adding 3.5% perchloric acid and
163 12.5 mM EDTA. Samples were neutralized to pH 6.5 by KOH and 0.3 M MOPS. ATP
164 was quantified using the Kinase-Glo Max Luminescence Kinase Assay (Promega)
165 and a Beckman Coulter's Paradigm Plate Reader. Part of the ATP produced by the
166 F_1F_0 -ATP synthase was assessed using oligomycin (20 μ g/mg of proteins).
167 Variations in transmembrane potential ($\Delta\Psi$) were evaluated in the respiration buffer
168 using Rhodamine 123 (0.5 μ g/ml), with λ^{exc} of 485 nm and λ^{em} of 533 nm under
169 constant stirring with a Cary Eclipse Fluorescence Spectrophotometer (Agilent
170 Technologies, Santa Clara, CA, USA) [37].

171 2.4. BN-PAGE analyses

172 Blue native-PAGE experiments were carried out as described [38]. 200 μ g of
173 mitochondrial proteins suspended in 100 μ l extraction buffer (30 mM HEPES pH=6,8,
174 150 mM potassium acetate, 12% glycerol, 2 mM 6-aminocaproic acid, 1 mM EGTA,
175 1.5% digitonin (Sigma)), supplemented with one protease inhibitor cocktail tablet from
176 Roche. After 30 min incubation on ice, the extracts were cleared by centrifugation
177 (14,000 rpm, 4°C, 30 min), supplemented with 4.5 μ l of loading dye (5% Serva Blue

178 G-250, 750 mM 6-aminocaproic acid) and run on NativePAGE™ 3-12% Bis-Tris Gels
179 (Invitrogen). After transfer onto a PVDF membrane, ATP synthase complexes were
180 detected using polyclonal antibodies raised against α -F1 subunit (Atp1p) or subunit *a*
181 (Atp6) of yeast ATP synthase, at 1:10000 dilution.

182 2.5. Amino-acid alignments and topology of subunit *a* mutations.

183 Multiple sequence alignment of ATP synthase *a*-subunits of various origins was
184 performed using COBALT [39]. The topology of the mutations within F_0 structure is
185 based on the atomic structure of F_0 recently published [5]. The shown figures were
186 built using PyMOL molecular graphic system.

187 2.6. Statistical analysis

188 At least three biological and three technical replicates for performed for all
189 experiments. The *t*-test was used for all data sets. Significance and confidence level
190 was set at 0.05.

191

192

193 **3. Results**

194 Yeast subunit *a* (also referred to as subunit 6 or Atp6p) is synthesized as a pre-
195 protein of which the first ten residues are removed during assembly [33]. The serine
196 residue at position 148 of human subunit *a* that is changed into asparagine by the
197 m.8969G>A mutation corresponds to *aS*₁₇₅ in the non-processed yeast protein (Fig.
198 1). As we have shown, a yeast model of the m.8969G>A mutation (*aS*₁₇₅N) fails to
199 grow on non-fermentable substrates like glycerol owing to a lack in *F*_O-mediated
200 proton transport [33]. Compared to wild type (*WT*) yeast, fully assembled *F*₁*F*_O
201 complexes accumulate slightly less in the *aS*₁₇₅N mutant and free *F*₁ particles are
202 detectable in BN-gels ([33], see also below). This effect may be in part or mostly due
203 to a higher propensity of the *aS*₁₇₅N mutant to produce ρ^-/ρ^0 cells issued from large
204 deletions in mtDNA (30% vs <5% in the *WT*). A decreased mtDNA stability was
205 observed in many other yeast mutants in which ATP synthase function is severely
206 compromised [40]. Thus, rather than a wide impact on ATP synthase structure, the
207 *aS*₁₇₅N mutation most likely locally disturbs this structure.


208 3.1. Isolation of revertants from the mutant *aS*₁₇₅N

209 We isolated revertants from the *aS*₁₇₅N mutant, using a previously described
210 procedure [41]. To ensure genetic independence, they were isolated from different
211 *aS*₁₇₅N subclones grown in liquid glucose. The cells were spread on glycerol medium
212 (10^8 cells/plate). Revertants appeared at a 10^{-7} frequency. 73 isolates were retained
213 for analysis. After crossing with a strain (D273-10B/60) having a wild type nucleus
214 and totally devoid of mitochondrial DNA (ρ^0), the revertants were still able to grow on
215 glycerol indicating that the suppressor mutations were nuclear dominant or located in
216 mitochondrial DNA. Most (>95%) of the spores from at least 6 complete tetrads
217 issued from the diploid revertants were able to grow on glycerol (not shown)

218 indicating that the suppressor mutations had a mitochondrial origin, otherwise they
219 would have displayed a mendelian (2:2) segregation. The gene *ATP6* was entirely
220 sequenced in each revertant. In 60 revertants, a novel mutation in *ATP6* (intragenic
221 suppressor) was identified (Table 2). Two nucleotide changes were introduced at
222 codon 175 to replace serine by asparagine (TCT₁₇₅AAT). Not surprisingly, none of
223 the sequenced revertants had recovered a wild type *ATP6* gene because the
224 frequency of a specific double nucleotide change is far below 10⁻¹⁰. However six
225 clones had again a serine codon at position 175 that was derived from a single
226 nucleotide change (AAT₁₇₅AGT); they all grew on glycerol like wild type yeast (not
227 shown) and were not analyzed further. Four other first-site mutations introduced
228 novel amino acid residues at position 175: AAT₁₇₅GAT (aN₁₇₅D) in two clones,
229 AAT₁₇₅AAA (aN₁₇₅K) in one clone, AAT₁₇₅ATT (aN₁₇₅I) in two clones, and AAT₁₇₅ACT
230 (aN₁₇₅T) in one clone. Henceforth, the four different pseudo first-site reversions will
231 be designated as aS₁₇₅D (instead of aN₁₇₅D), aS₁₇₅K, aS₁₇₅I, and aS₁₇₅T to indicate
232 the amino-acid changes relative to the wild type protein sequence.

233 In 48 revertants, respiration-dependent growth recovery resulted from a single
234 nucleotide change in *ATP6* not located at codon 175 (second-site intragenic
235 suppressor): CCA₁₂TCA (aP₁₂S) in 3 clones, ATT₁₇₁TTT (aI₁₇₁F) in 8 clones,
236 ATT₁₇₁AAT (aI₁₇₁N) in 1 clone, ATT₂₃₉TTT (aI₂₃₉F) in 35 clones, and ATT₂₀₀ATA
237 (aI₂₀₀M) in 1 clone (Fig. 1, Table 2).

238 Finally, the remaining 13 revertants had no other mutation in *ATP6* than the
239 original one, aS₁₇₅N. We considered the possibility that these revertants were issued
240 from an extragenic suppressor in one of the two other mitochondrial ATP synthase
241 genes, *ATP8* and *ATP9*, but no mutation was detected in these genes. These
242 revertants were not analyzed further.



243 **Figure 1. Sequence alignments of subunits *a* from various sources and**
 244 **conservation of the residues modified by the suppressors of S₁₇₅N.** The aligned
 245 subunits *a* are from *Homo sapiens* (H.s.), *Bos taurus* (B.t.), *Saccharomyces*
 246 *cerevisiae* (S.c.), *Schizosaccharomyces pombe* (S.p.), *Yarrowia lipolytica* (Y.l.) and
 247 *Escherichia coli* (E.c.). The magenta and green arrows mark the locations of the
 248 pseudo first-site and the second-site intragenic mutations found in this study,
 249 respectively. The maroon arrow marks the original S₁₇₅N mutation. At the top and
 250 bottom, the residues are numbered according to the unprocessed S.c. protein (the
 251 first 10 residues are cleaved during assembly of the protein [42] and to E.c. protein,
 252 respectively. Leader peptide sequences in the subunits *a* of S.c., S.p. and Y.l. [43]
 253 are marked in yellow. Strictly conserved residues are in white characters on a red
 254 background while similar residues are in red on a white background with blue frames.


255 α -helices in the *S.c.* and *E.c.* proteins, marked above and below amino the
256 alignment, are according to *Y.l.* and *E.c.* structures, respectively [2, 5, 44]. The
257 essential arginine is on a blue background.

258

259 3.2. Properties of the revertants.

260 3.2.1. Respiratory growth and mtDNA stability

261 Of the nine different intragenic suppressors we isolated from the *aS*₁₇₅N mutant, four
262 (*aS*₁₇₅I, *aS*₁₇₅T, *aI*₁₇₁F, and *I*₂₀₀M) conferred a good growth on glycerol whereas the
263 others (*aS*₁₇₅D, *aS*₁₇₅K, *aP*₁₂S, *aI*₂₃₉F, and *aI*₁₇₁N) resulted in a slow respiratory
264 growth phenotype, at all temperatures tested (20°C, 28°C, 36°C) (shown for 28°C in
265 Fig. 2A,B)). All the revertants had a much better genetic stability than the *aS*₁₇₅N
266 mutant as evidenced by a reduced accumulation of ρ^-/ρ^0 cells in cultures (10% or less
267 vs 35%) (Table 3).



268


269 **Figure 2. Growth of mutant strains.** (A) Fresh liquid glucose cultures of wild type
270 yeast, mutant *aS*₁₇₅N and its revertants were serially diluted and spotted on rich
271 glucose and rich glycerol/ethanol plates. The glucose and glycerol plates were
272 photographed after 3 and 7 days of incubation at 28°C, respectively. (B) Growth
273 curves in liquid rich glycerol/ethanol at 28°C.

274

275 3.2.2. Respiration and ATP synthesis

276 Improvement of ATP synthase function by the suppressors was evaluated first by
277 measuring oxygen consumption and ATP synthesis rates in isolated mitochondria. As
278 shown previously, yeast *atp6* mutations including *aS₁₇₅N* that compromise ATP
279 synthase activity usually result in a diminished respiration rate mainly because of a
280 lower content in complex IV ([15, 29, 33, 45] Table 3). Thus, decreased ATP
281 synthesis rate in *atp6* mutants is not primarily due to a reduced rate of electron
282 transfer to oxygen but to some defect in the ATP synthase that secondarily impacts
283 respiration. Oxygen consumption was assessed with NADH as an electron donor,
284 alone (basal, state 4 respiration), after further addition (75 μ M) of ADP (state 3,
285 phosphorylating conditions) or in the presence of the membrane proton ionophore
286 CCCP (carbonyl cyanide *m*-chlorophenylhydrazone) (uncoupled respiration). Under
287 state 4, respiration is controlled by the passive permeability to protons of the inner
288 membrane. Under state 3, most of the protons return to the matrix through the ATP
289 synthase so that the contribution to respiration of passive proton leaks becomes very
290 small. In the presence of CCCP, the maintenance of an electrical potential ($\Delta\Psi$)
291 across the inner membrane is impossible and respiration becomes maximal. We also
292 measured complex IV activity using ascorbate/TMPD (N,N,N',N'-tetramethyl-
293 phenylenediamine) in the presence of CCCP. Mitochondrial ATP synthesis rate was
294 measured using NADH as a respiratory substrate in the presence of a large excess
295 (750 μ M) of external ADP, conditions under which ATP is synthesized exclusively by
296 ATP synthase using the proton-motive force generated by complexes III and IV (there
297 is no complex I in *S. cerevisiae*).

298 Consistent with their good growth on glycerol, mitochondria from strains
299 *aS₁₇₅I*, *aS₁₇₅T*, *aS₁₇₅N+a₁₇₁F* and *aS₁₇₅N+a₂₀₀M* efficiently respired and produced
300 ATP almost like those from wild type yeast (Table 3). Accordingly, in all the slowly
301 growing revertants ATP synthesis rate was diminished by 80-90% compared to the
302 *WT*. ATP synthase assembled and accumulated quite efficiently in all the revertants
303 (Fig. 3). Regarding the Westerns with Atp6 antibodies, it apparently seems that there
304 is much less ATP synthase in the *aP₁₂S* revertant whereas the Atp1 antibodies did
305 not reveal a lack of this enzyme in this strain. The most likely explanation is that the
306 *aP₁₂S* mutation is within the sequence of subunit *a* (a.a. 11-23) that we used to raise
307 the Atp6 antibodies, and that because of this these antibodies reacted less efficiently
308 with the *aP₁₂S* subunit.



309 **Figure 3. Levels of ATP synthase in the revertants.** Proteins were extracted from
310 the mitochondrial samples used in the bioenergetics experiments described in Table
311 3 with 1.5 gr digitonin per gr of proteins and separated by BN-PAGE (200 μ g per
312 lane). The proteins were transferred onto PVDF membrane and probed with
313 antibodies against subunit *a* (Atp6) or F1-subunit Atp1 of ATP synthase, revealing
314 dimeric (V_2) and monomeric (V_1) F_1F_0 complexes. The shown Westerns are
315 representative of three independent experiments.


316

317 3.2.3. Membrane potential

318 The influence of the suppressor mutations was investigated further using Rhodamine
319 123, a fluorescent cationic dye that can be used to monitor changes in mitochondrial
320 membrane potential ($\Delta\Psi$) [37]. Increasing $\Delta\Psi$ is followed by the uptake of the dye
321 inside the matrix and concomitant fluorescence quenching. In a first set of
322 experiments (Fig. 4A), we tested the capacity of externally added ADP to induce $\Delta\Psi$
323 consumption. To this end, mitochondria were first fed with electrons from ethanol.
324 Due to their strongly reduced capacity to respire, those from the mutant *aS*₁₇₅N were
325 poorly energized in comparison to *WT* mitochondria whereas ethanol induced a much
326 larger $\Delta\Psi$ variation in all the revertants. Normally, further adding a small amount of
327 ADP induces a transient fluorescence increase due to $\Delta\Psi$ consumption by the ATP
328 synthase during phosphorylation of the added ADP. This was indeed observed in
329 mitochondria from the *WT* and the revertants, whereas those from the *aS*₁₇₅N mutant
330 were virtually insensitive to ADP consistent with their very poor capacity to produce
331 ATP (Table 3). However, in those revertants growing slowly on glycerol (*aS*₁₇₅D,
332 *aS*₁₇₅K, *aS*₁₇₅N+*aP*₁₂S, *aS*₁₇₅N+*aI*₂₃₉F, and *aS*₁₇₅N+*aI*₁₇₁N) a much longer time was
333 needed to recover the ethanol-induced $\Delta\Psi$ compared to the *WT* and the revertants

334 with a good growth on glycerol (*aS*₁₇₅I, *aS*₁₇₅T, *aS*₁₇₅N+*aI*₁₇₁F, and *aS*₁₇₅N+*aI*₂₀₀M),
 335 reflecting the large differences in ATP synthesis rate between these strains. KCN
 336 was then added to inhibit complex IV, which, in mitochondria from the *WT* and the
 337 revertants resulted in a partial $\Delta\Psi$ collapse. The remaining potential was due to F_0 -
 338 mediated proton pumping coupled to hydrolysis of the ATP that accumulated in the
 339 mitochondrial matrix during phosphorylation of the added ADP, as evidenced by the
 340 loss of this potential by inhibiting ATP synthase with oligomycin. By contrast, no
 341 oligomycin-sensitive $\Delta\Psi$ was observed in the *aS*₁₇₅N mitochondria owing to their
 342 incapacity to produce ATP.

343 In a second set of experiments (Fig. 4B), we directly tested the proton-
 344 pumping activity of ATP synthase using externally added ATP independently of the
 345 respiratory chain. To this end, mitochondria were first energized with ethanol to
 346 remove the natural inhibitory peptide (IF1) of F_1 -ATPase. $\Delta\Psi$ was then collapsed with
 347 KCN, and less than one minute later, thus well before IF1 rebinding [46], ATP was
 348 added. External ATP is counter-exchanged against ADP present in the matrix by the
 349 ADP/ATP translocase, which does not require any $\Delta\Psi$, and the ATP can then be
 350 hydrolyzed by F_1 coupled to F_0 -mediated proton transport. Adding ATP promoted in
 351 mitochondria from the *WT* and the revertants a large and stable fluorescence
 352 quenching of the dye that was reversed upon inhibition with oligomycin, whereas
 353 *aS*₁₇₅N mitochondria were mostly insensitive to ATP due to their inability to move
 354 protons through the F_0 .



355 **Figure 4. Mitochondrial membrane potential.** Variations in mitochondrial $\Delta\Psi$ were
356 monitored by fluorescence quenching of Rhodamine 123 in the mitochondria used for
357 the bioenergetics experiments described in Table 3. The tracings in panel A show
358 how the mitochondria respond to the addition of ADP, those in panel B reflect the
359 proton-pumping activity of ATP synthase. The additions were 75 μ M ADP, 0.5 μ g/ml
360 Rhodamine 123, 75 μ g/mL mitochondrial proteins (Mito), 10 μ L ethanol (EtOH), 2 mM
361 potassium cyanide (KCN), 4 μ g/mL oligomycin (oligo), and 4 μ M carbonyl cyanide-m-
362 chlorophenyl hydrazone (CCCP). The shown tracings are representative of three
363 experiments.

364

365 3.3. Topological location of the mutations

366 The locations in the recently published atomic structure of yeast F_0 [5] of the
367 mutations here described (*aS*₁₇₅N, *aS*₁₇₅D, *aS*₁₇₅K, *aS*₁₇₅I, *aS*₁₇₅N, *aP*₁₂S, *aI*₁₇₁F,
368 *aI*₁₇₁N, *aI*₂₃₉F, and *aI*₂₀₀M) are shown in Fig. 5. The amino acid alignments in Fig. 1
369 establish the correspondences with human subunit *a* residues. The six membrane-
370 associated helices of subunit *a* and the two transmembrane helices of subunit *c* are
371 referred to as *aH*1-6 and *cTM*1-2 respectively (Fig. 5A). At the interface between the
372 *a*-subunit and the *c*-ring, near the middle of the membrane, are two electrically
373 charged residues (*aR*₁₈₆ and *cE*₅₉) directly involved in proton translocation. Being
374 kinked, *aH*5 (residues 162-209) can follow the curvature of the *c*-ring and seal the
375 two hydrophilic pockets that connect the *a/c*-ring interface to the intermembrane and
376 matrix spaces. The N-term part of *aH*5 (residues 162-180, 31 Å long) is shorter than
377 its C-term part (residues 184-209, 43 Å long), and *aH*6 (residues 219-257, 55 Å) is
378 shorter and more straight than *aH*5, which creates a funnel-shaped cleft between
379 subunit *a* and the *c*-ring accessible from the matrix (Fig. 5B). The mouth of this cleft

380 is surrounded by a short helix $aH\beta$ (residues 137-147) that connects $aH4$ and $aH5$,
381 the C-terminal extremity of subunit a , and a five amino acid long loop (residues 85-
382 89) between $aH2$ and $aH3$. The cleft, into which points the essential aR_{186} residue, is
383 15 Å long (from aR_{186} to aD_{254} or E_{172}), 8 Å wide (from aD_{254} to aE_{172}) and 16 Å deep
384 (from aS_{175} to the C-terminus of the protein). It is bordered by polar or electrically
385 charged residues on $aH5$ (aS_{250} , aY_{251} , aK_{253} , aD_{254} , aH_{259}) and $aH6$ (aE_{172} , aS_{175} ,
386 aR_{179} , aS_{182}), two of which, aE_{172} and aD_{254} , would be essential for moving protons
387 out of the cleft [5, 34] (Fig. 5B,D). Since the others, as well as those surrounding cE_{59}
388 (cF_{48} , cP_{49} , cI_{52} , cL_{53} , cF_{55} , cA_{56} , cL_{57}), cannot engage in hydrogen bonding, it is
389 possible that water molecules inside the cleft help proton conduction towards the
390 matrix.

391 Although aS_{175} is highly conserved (Fig. 1), has a hydroxyl group that can
392 exchange protons and is located in the n -side cleft, this residue is clearly not required
393 for F_O -mediated proton translocation. Indeed, as shown in this study, ATP synthase
394 function was fully preserved with the presence at position 175 of an aliphatic side
395 chain residue (aI_{175}). These findings are in line with a previous study showing that
396 replacing the equivalent serine in subunit a of *E. coli* by alanine had no detrimental
397 consequences [47]. aI_{175} can orient towards the c -ring without any steric hindrance
398 on E_{172} and preserve with aL_{164} , aL_{167} and aI_{171} a non-polar environment around the
399 c -ring (Fig. 5D). The absence of major functional defects with a threonine residue at
400 position 175 (aT_{175}) further supports a non-essential role for aS_{175} .


401 Disruption of F_O -mediated proton transport induced by aN_{175} possibly results
402 from the establishment of two hydrogen bonds between aN_{175} amide and aE_{172}
403 carboxylate groups that are distant by 3.1 and 3.3 Å (Fig. 5B,C). As a result the
404 glutamate would become unable to conduct protons out of the n -side cleft.

405 Alternatively, aN_{175} can orient towards the c -ring without making a direct hydrogen
406 bond with the catalytic cE_{59} residue (because of a too long distance, 4 Å) (Fig. 5D).
407 However, it will then impair rotation of the c -ring by clashing cA_{56} and cL_{57} . Like
408 aN_{175} , aD_{175} can adopt the same two orientations towards either aE_{172} or the c -ring.
409 However the electrostatic repulsion between aD_{175} and aE_{172} most likely favors the
410 second one, which may explain the recovery of ATP synthase function when aN_{175} is
411 replaced by aspartate. The poor suppressor activity of aD_{175} is possibly due to
412 clashes with the c -ring and/or unproductive proton transfers. The suppressor activity
413 of aK_{175} probably also result from the recovery of aE_{172} to conduct protons. Owing to
414 its flexibility and hydrophobic alkyl moiety, the lysine side chain may easily adopt a
415 conformation that preserves c -ring rotation. However due to its positive charge, a
416 reduced strength of attraction for protons towards the matrix may be responsible for
417 the slow and inefficient functioning of ATP synthase with aK_{175} .

418 The five-second site suppressors that make the $aS_{175}N$ mutation no longer or
419 less detrimental all localize close to the a/c interface (Fig. 5E,F). Two are in proximity
420 to the original mutation, at position 171 ($aI_{171}F$ and $aI_{171}N$). ATP synthase function
421 was fully restored with aF_{171} . Replacement of aI_{171} by a rigid and bulkier
422 phenylalanine group may structurally shift the position of aN_{175} towards the c -ring so
423 as it can no longer interact with aE_{172} without affecting the sealing of the two
424 hydrophilic pockets by $aH5$. Furthermore, as a highly hydrophobic residue,
425 phenylalanine preserves the non-polar surface that $aH5$ (aL_{164} , aL_{167} , aL_{168} , aI_{171} ,
426 aL_{174} , aA_{178} , aA_{193} , aL_{197} , aI_{200} , aL_{201} , and aL_{204}) and $aH6$ (aM_{225} , aI_{229} , aL_{232} , aI_{236} ,
427 aI_{239}) provide in front of the c -ring so as to ease its rotation. The suppressor activity of
428 aN_{171} is much less efficient compared to aF_{171} , indicating that aN_{175} remains mostly

429 bound to aE_{172} and that the proton exchanging capacity of aN_{171} helps somehow the
430 protons to quit the *c*-ring.

431 The three other second-site suppressors are remotely located from the original
432 $aS_{175}N$ mutation, by 35 Å ($aP_{12}S$, $aI_{200}M$) or 23 Å ($aI_{239}F$) on the *p*-side of the
433 membrane (Fig. 5E). They are quite close to conserved residues presumably
434 involved in the transport of protons from the intermembrane space (aE_{233} (H in *E.*
435 *coli*), aN_{190} , aQ_{240} and aH_{195} (E in *E. coli*)) to aR_{186} . Interestingly, the $aP_{12}S$
436 suppressor belongs to a region of subunit *a* that does not exist in bovine and humans
437 (Fig. 1). That it can upon mutation compensate for the $aS_{175}N$ change indicates that
438 this region has an important function in yeast ATP synthase. Consistently, this region
439 shows a rather good amino acid sequence conservation in those mitochondria where
440 it is present. While it is difficult to provide a mechanistic explanation for these long-
441 distance interactions that improve F_O -mediated proton transfer in the $aS_{175}N$ mutant
442 this is, as discussed below, an interesting observation.



443

444 **Figure 5. Topological locations of the mutations.** (A) View of the entire c-ring and
 445 subunit a from the matrix and of the pathway along which protons are transported
 446 from the intermembrane space to the mitochondrial matrix. The side chains of the two
 447 residues essential to this transfer (aR₁₈₆ and cE₅₉) are drawn as stick with their
 448 carbon atoms in white. The p-side and n-side clefts are shown as grey surface. (B)
 449 The original aS₁₇₅N mutation prevents by hydrogen bonding the nearby glutamate
 450 aE₁₇₂ to move protons out the n-side cleft. (C) Zoom on the hydrogen bonds that

451 aN_{175} can potentially form with aE_{172} (D) View from the matrix showing the two
452 possible orientations of aN_{175} towards either the *c*-ring (yellow) or aE_{172} (magenta).
453 aF_{171} (yellow) is supposed to orient aN_{175} towards the *c*-ring, thus restoring the proton
454 conducting activity of aE_{172} , whereas aN_{175} remains oriented towards aE_{172} with aN_{171}
455 (magenta). (E) Enlargement of the region showing the five mutated residues (aS_{175} ,
456 aP_{12} , aI_{171} , aI_{200} , and aI_{239}); their side chains are drawn as stick with their carbon
457 atoms in yellow. Residues presumed to be important for proton transfer (aE_{172} , aD_{234} ,
458 aH_{195} and aD_{254}) are represented as stick with their carbon atoms in white color. (F)
459 Enlargement around the $aP_{12}S$, $aI_{200}M$ and $aI_{239}F$ second-site suppressors.

460

461 **4. Conclusion**

462 With the recently described cryo-EM structures of F_1F_0 ATP synthase from various
463 mitochondrial origins it has become feasible to map at a molecular level discrete
464 structural changes of this enzyme found to be responsible for human diseases.
465 Although this is a major step towards a better comprehension of these diseases, it is
466 generally difficult to understand how loss-of-function mutations act. The suppressor
467 genetics approach used in this study help to understand how a pathogenic mutation
468 in subunit *a* ($aS_{148}N$ in humans, $aS_{175}N$ in yeast) disrupts F_0 -mediated proton
469 conduction. Our results reveal that despite its very strong evolutionary conservation
470 and its capacity to exchange protons thanks to the presence of a hydroxyl group on
471 its side chain, the mutated serine is by itself not directly involved in this activity.
472 Indeed, consistent with a previous study in *E. coli* [47], ATP synthase function was
473 fully regained by replacing the mutant asparagine with aliphatic residues that do not
474 have the capacity to conduct protons. Thus, losing the serine is by itself not
475 problematic, it is its replacement by asparagine that leads to the loss of F_0 function.

476 The most likely explanation that emerges from our suppressor genetic analysis and
477 the atomic structure of yeast F_0 , is that the mutant asparagine neutralizes by
478 hydrogen bonding the nearby glutamate (aE_{172}) presumed to be critical for the exit of
479 protons from the n -side hydrophilic cleft.

480 Very interestingly also, we show that the serine-to-asparagine change can be
481 somewhat efficiently suppressed by mutations in other positions of subunit a
482 (second-site suppressors). Thus, while being still present, the mutant asparagine
483 ceases to be or is much less detrimental. Surprisingly, some of the second-site
484 suppressors are within the p -side cleft that provides a pathway for protons from the
485 intermembrane space. These suppressors must thus be responsible for long (20-30
486 Å)-range effects that somehow disrupt the detrimental hydrogen bond between
487 aE_{172} and aN_{175} or help the protons to find another route to reach the mitochondrial
488 matrix. It is not unreasonable to imagine that drugs could as well undo an
489 undesirable hydrogen bond by hitting the regions of subunit a modified by the
490 suppressors. The approach used in this study is not only helpful to better understand
491 how mutations of ATP synthase induce diseases, but may also open the door to
492 drug-design therapeutic developments.

493

494

495 **Acknowledgements**

496 This work was supported by grants from National Science Center of Poland
497 (2016/23/B/NZ3/02098) to R.K, AFM (Association Française contre les Myopathies)
498 to J.-P.dR, Agence Nationale de la Recherche to M.-F.G. (ANR-12-BSV8-024),
499 National Natural Science Foundation (NSF) Grant (81370788 & 8151101098) to H.C.
500 N.S. and K.B. were supported by the Polonium grant 35301WC, Ministère Français
501 de l'Enseignement Supérieur et de la Recherche, and Ministry of Science and Higher
502 Education of Poland.

503 **Author Contributions**

504 N.S., K.B., F.G., M.B., S.X., J.-P.L., D.T.-T., and H.C. isolated the revertants and
505 analyzed their properties; A.D. performed the structural modeling analyses with a
506 financial support provided by M.-F. G.; J.-P.dR. and R.K. designed the research;
507 A.D., R.K. and J.-P.dR wrote the paper.

508

509 **References**

- 510
511 [1] P.D. Boyer, The ATP synthase--a splendid molecular machine, *Annu. Rev. Biochem.*, 66 (1997)
512 717-749.
513 [2] A. Hahn, K. Parey, M. Bublitz, D.J. Mills, V. Zickermann, J. Vonck, W. Kuhlbrandt, T. Meier,
514 Structure of a Complete ATP Synthase Dimer Reveals the Molecular Basis of Inner Mitochondrial
515 Membrane Morphology, *Mol. Cell.*, 63 (2016) 445-456.
516 [3] E. Morales-Rios, I.N. Watt, Q. Zhang, S. Ding, I.M. Fearnley, M.G. Montgomery, M.J. Wakelam,
517 J.E. Walker, Purification, characterization and crystallization of the F-ATPase from *Paracoccus*
518 *denitrificans*, *Open Biol.*, 5 (2015) 150119.
519 [4] A. Zhou, A. Rohou, D.G. Schep, J.V. Bason, M.G. Montgomery, J.E. Walker, N. Grigorieff, J.L.
520 Rubinstein, Structure and conformational states of the bovine mitochondrial ATP synthase by cryo-
521 EM, *eLife*, 4 (2015).
522 [5] H. Guo, S.A. Bueler, J.L. Rubinstein, Atomic model for the dimeric FO region of mitochondrial
523 ATP synthase, *Science*, 358 (2017) 936-940.
524 [6] M. Allegretti, N. Klusch, D.J. Mills, J. Vonck, W. Kuhlbrandt, K.M. Davies, Horizontal membrane-
525 intrinsic alpha-helices in the stator a-subunit of an F-type ATP synthase, *Nature*, 521 (2015) 237-
526 240.
527 [7] M. Strauss, G. Hofhaus, R.R. Schroder, W. Kuhlbrandt, Dimer ribbons of ATP synthase shape the
528 inner mitochondrial membrane, *EMBO j.*, 27 (2008) 1154-1160.
529 [8] K.M. Davies, M. Strauss, B. Daum, J.H. Kief, H.D. Osiewacz, A. Rycovska, V. Zickermann, W.
530 Kuhlbrandt, Macromolecular organization of ATP synthase and complex I in whole mitochondria,
531 *Proc. Natl. Acad. Sci. U.S.A.*, 108 (2011) 14121-14126.

532 [9] S.B. Vik, B.J. Antonio, A mechanism of proton translocation by F₁F₀ ATP synthases suggested by
533 double mutants of the a subunit, *J. Biol. Chem.*, 269 (1994) 30364-30369.

534 [10] W. Junge, H. Lill, S. Engelbrecht, ATP synthase: an electrochemical transducer with rotatory
535 mechanics, *Trends Biochem. Sci.*, 22 (1997) 420-423.

536 [11] N. Mitome, S. Ono, H. Sato, T. Suzuki, N. Sone, M. Yoshida, Essential arginine residue of the
537 F(o)-a subunit in F(o)F(1)-ATP synthase has a role to prevent the proton shortcut without c-ring
538 rotation in the F(o) proton channel, *Biochem. J.*, 430 (2010) 171-177.

539 [12] D. Pogoryelov, A. Krahl, J.D. Langer, O. Yildiz, J.D. Faraldo-Gomez, T. Meier, Microscopic rotary
540 mechanism of ion translocation in the F(o) complex of ATP synthases, *Nature Chem. Biol.*, 6 (2010)
541 891-899.

542 [13] E. Morales-Rios, M.G. Montgomery, A.G. Leslie, J.E. Walker, Structure of ATP synthase from
543 *Paracoccus denitrificans* determined by X-ray crystallography at 4.0 Å resolution, *Proc. Natl. Acad.
544 Sci. U.S.A.*, 112 (2015) 13231-13236.

545 [14] J.P. Abrahams, A.G. Leslie, R. Lutter, J.E. Walker, Structure at 2.8 Å resolution of F₁-ATPase
546 from bovine heart mitochondria, *Nature*, 370 (1994) 621-628.

547 [15] R. Kucharczyk, M. Zick, M. Bietenhader, M. Rak, E. Couplan, M. Blondel, S.D. Caubet, J.P. di
548 Rago, Mitochondrial ATP synthase disorders: molecular mechanisms and the quest for curative
549 therapeutic approaches, *Biochim. Biophys. Acta.*, 1793 (2009) 186-199.

550 [16] F.J. Miller, F.L. Rosenfeldt, C. Zhang, A.W. Linnane, P. Nagley, Precise determination of
551 mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack
552 of change of copy number with age, *Nuc. Acids Res.*, 31 (2003) e61.

553 [17] L.M. Steinmetz, C. Scharfe, A.M. Deutschbauer, D. Mokranjac, Z.S. Herman, T. Jones, A.M. Chu,
554 G. Giaever, H. Prokisch, P.J. Oefner, R.W. Davis, Systematic screen for human disease genes in
555 yeast, *Nat. Genet.*, 31 (2002) 400-404.

556 [18] J. Reinders, R.P. Zahedi, N. Pfanner, C. Meisinger, A. Sickmann, Toward the complete yeast
557 mitochondrial proteome: multidimensional separation techniques for mitochondrial proteomics, *J
558 Proteome Res.*, 5 (2006) 1543-1554.

559 [19] H. Prokisch, C. Scharfe, D.G. Camp, 2nd, W. Xiao, L. David, C. Andreoli, M.E. Monroe, R.J.
560 Moore, M.A. Gritsenko, C. Kozany, K.K. Hixson, H.M. Mottaz, H. Zischka, M. Ueffing, Z.S. Herman,
561 R.W. Davis, T. Meitinger, P.J. Oefner, R.D. Smith, L.M. Steinmetz, Integrative analysis of the
562 mitochondrial proteome in yeast, *PLoS Biol.*, 2 (2004) e160.

563 [20] D.J. Pagliarini, S.E. Calvo, B. Chang, S.A. Sheth, S.B. Vafai, S.E. Ong, G.A. Walford, C. Sugiana, A.
564 Boneh, W.K. Chen, D.E. Hill, M. Vidal, J.G. Evans, D.R. Thorburn, S.A. Carr, V.K. Mootha, A
565 mitochondrial protein compendium elucidates complex I disease biology, *Cell*, 134 (2008) 112-123.

566 [21] H.W. Rhee, P. Zou, N.D. Udeshi, J.D. Martell, V.K. Mootha, S.A. Carr, A.Y. Ting, Proteomic
567 mapping of mitochondria in living cells via spatially restricted enzymatic tagging, *Science*, 339
568 (2013) 1328-1331.

569 [22] N. Bonnefoy, T.D. Fox, Genetic transformation of *Saccharomyces cerevisiae* mitochondria,
570 *Meth. Cell Biol.*, 65 (2001) 381-396.

571 [23] K. Okamoto, P.S. Perlman, R.A. Butow, The sorting of mitochondrial DNA and mitochondrial
572 proteins in zygotes: preferential transmission of mitochondrial DNA to the medial bud, *J. Cell Biol.*,
573 142 (1998) 613-623.

574 [24] M.G. Baile, S.M. Claypool, The power of yeast to model diseases of the powerhouse of the cell,
575 *Front. Biosci. (Landmark Ed)*, 18 (2013) 241-278.

576 [25] J.P. Lasserre, A. Dautant, R.S. Aiyar, R. Kucharczyk, A. Glatigny, D. Tribouillard-Tanvier, J.
577 Rytka, M. Blondel, N. Skoczen, P. Reynier, L. Pitayau, A. Rotig, A. Delahodde, L.M. Steinmetz, G.
578 Dujardin, V. Procaccio, J.P. di Rago, Yeast as a system for modeling mitochondrial disease
579 mechanisms and discovering therapies, *D.M.M.*, 8 (2015) 509-526.

580 [26] A.M. Kabala, J.P. Lasserre, S.H. Ackerman, J.P. di Rago, R. Kucharczyk, Defining the impact on
581 yeast ATP synthase of two pathogenic human mitochondrial DNA mutations, T9185C and T9191C,
582 *Biochimie*, 100 (2014) 200-206.

583 [27] R. Kucharczyk, N. Ezkurdia, E. Couplan, V. Procaccio, S.H. Ackerman, M. Blondel, J.P. di Rago,
584 Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast
585 mitochondrial ATP synthase, *Biochim. Biophys. Acta*, 1797 (2010) 1105-1112.

586 [28] R. Kucharczyk, M.F. Giraud, D. Brethes, M. Wysocka-Kapcinska, N. Ezkurdia, B. Salin, J.
587 Velours, N. Camougrand, F. Haraux, J.P. di Rago, Defining the pathogenesis of human mtDNA
588 mutations using a yeast model: the case of T8851C, *Int. J. Biochem. Cell Biol.*, 45 (2013) 130-140.

589 [29] R. Kucharczyk, M. Rak, J.P. di Rago, Biochemical consequences in yeast of the human
590 mitochondrial DNA 8993T>C mutation in the ATPase6 gene found in NARP/MILS patients, *Biochim.*
591 *Biophys. Acta*, 1793 (2009) 817-824.

592 [30] R. Kucharczyk, B. Salin, J.P. di Rago, Introducing the human Leigh syndrome mutation T9176G
593 into *Saccharomyces cerevisiae* mitochondrial DNA leads to severe defects in the incorporation of
594 Atp6p into the ATP synthase and in the mitochondrial morphology, *Hum. Mol. Genet.*, 18 (2009)
595 2889-2898.

596 [31] K. Niedzwiecka, A.M. Kabala, J.P. Lasserre, D. Tribouillard-Tanvier, P. Golik, A. Dautant, J.P. di
597 Rago, R. Kucharczyk, Yeast models of mutations in the mitochondrial ATP6 gene found in human
598 cancer cells, *Mitochondrion*, 29 (2016) 7-17.

599 [32] M. Rak, E. Tetaud, S. Duvezin-Caubet, N. Ezkurdia, M. Bietenhader, J. Rytka, J.P. di Rago, A
600 yeast model of the neurogenic ataxia retinitis pigmentosa (NARP) T8993G mutation in the
601 mitochondrial ATP synthase-6 gene, *J. Biol. Chem.*, 282 (2007) 34039-34047.

602 [33] S. Wen, K. Niedzwiecka, W. Zhao, S. Xu, S. Liang, X. Zhu, H. Xie, D. Tribouillard-Tanvier, M.F.
603 Giraud, C. Zeng, A. Dautant, R. Kucharczyk, Z. Liu, J.P. di Rago, H. Chen, Identification of G8969>A in
604 mitochondrial ATP6 gene that severely compromises ATP synthase function in a patient with IgA
605 nephropathy, *Sci. Rep.*, 6 (2016) 36313.

606 [34] A.P. Srivastava, M. Luo, W. Zhou, J. Symersky, D. Bai, M.G. Chambers, J.D. Faraldo-Gomez, M.
607 Liao, D.M. Mueller, High-resolution cryo-EM analysis of the yeast ATP synthase in a lipid
608 membrane, *Science*, (2018)

609 [35] B. Guerin, P. Labbe, M. Somlo, Preparation of yeast mitochondria (*Saccharomyces cerevisiae*)
610 with good P/O and respiratory control ratios, *Meth. Enzym.*, 55 (1979) 149-159.

611 [36] M. Rigoulet, B. Guerin, Phosphate transport and ATP synthesis in yeast mitochondria: effect of
612 a new inhibitor: the tribenzylphosphate, *FEBS Letters*, 102 (1979) 18-22.

613 [37] R.K. Emaus, R. Grunwald, J.J. Lemasters, Rhodamine 123 as a probe of transmembrane
614 potential in isolated rat-liver mitochondria: spectral and metabolic properties, *Biochim. Biophys.*
615 *Acta*, 850 (1986) 436-448.

616 [38] H. Schagger, G. von Jagow, Blue native electrophoresis for isolation of membrane protein
617 complexes in enzymatically active form, *Anal. Biochem.*, 199 (1991) 223-231.

618 [39] I. Bohovych, O. Khalimonchuk, Sending Out an SOS: Mitochondria as a Signaling Hub, *Front.*
619 *Cell Dev. Biol.*, 4 (2016) 109.

620 [40] V. Contamine, M. Picard, Maintenance and integrity of the mitochondrial genome: a plethora
621 of nuclear genes in the budding yeast, *M.M.B.R.*, 64 (2000) 281-315.

622 [41] J.P. di Rago, P. Netter, P.P. Slonimski, Pseudo-wild type revertants from inactive
623 apocytochrome b mutants as a tool for the analysis of the structure/function relationships of the
624 mitochondrial ubiquinol-cytochrome c reductase of *Saccharomyces cerevisiae*, *J. Biol. Chem.*, 265
625 (1990) 3332-3339.

626 [42] T. Michon, M. Galante, J. Velours, NH2-terminal sequence of the isolated yeast ATP synthase
627 subunit 6 reveals post-translational cleavage, *Eur. J. Biochem. / FEBS*, 172 (1988) 621-625.

628 [43] S. Liu, T.J. Charlesworth, J.V. Bason, M.G. Montgomery, M.E. Harbour, I.M. Fearnley, J.E.
629 Walker, The purification and characterization of ATP synthase complexes from the mitochondria of
630 four fungal species, *Biochem. J.*, 468 (2015) 167-175.

631 [44] M. Sobti, C. Smits, A.S. Wong, R. Ishmukhametov, D. Stock, S. Sandin, A.G. Stewart, Cryo-EM
632 structures of the autoinhibited *E. coli* ATP synthase in three rotational states, *eLife*, 5 (2016).

633 [45] M. Bietenhader, A. Martos, E. Tetaud, R.S. Aiyar, C.H. Sellem, R. Kucharczyk, S. Clauder-
634 Munster, M.F. Giraud, F. Godard, B. Salin, I. Sagot, J. Gagneur, M. Dequard-Chablat, V. Contamine,
635 S. Hermann-Le Denmat, A. Sainsard-Chanet, L.M. Steinmetz, J.P. di Rago, Experimental relocation
636 of the mitochondrial ATP9 gene to the nucleus reveals forces underlying mitochondrial genome
637 evolution, *PLoS Genet.*, 8 (2012) e1002876.

638 [46] R. Venard, D. Brethes, M.F. Giraud, J. Vaillier, J. Velours, F. Haraux, Investigation of the role
639 and mechanism of IF1 and STF1 proteins, twin inhibitory peptides which interact with the yeast
640 mitochondrial ATP synthase, *Biochemistry*, 42 (2003) 7626-7636.

641 [47] S.B. Vik, B.D. Cain, K.T. Chun, R.D. Simoni, Mutagenesis of the alpha subunit of the F1Fo-
642 ATPase from *Escherichia coli*. Mutations at Glu-196, Pro-190, and Ser-199, *J. Biol. Chem.*, 263
643 (1988) 6599-6605.

644 [48] M. Rak, E. Tetaud, F. Godard, I. Sagot, B. Salin, S. Duvezin-Caubet, P.P. Slonimski, J. Rytka, J.P.
645 di Rago, Yeast cells lacking the mitochondrial gene encoding the ATP synthase subunit 6 exhibit a
646 selective loss of complex IV and unusual mitochondrial morphology, *J. Biol. Chem.*, 282 (2007)
647 10853-10864.

648 [49] J.P. van Dijken, J. Bauer, L. Brambilla, P. Duboc, J.M. Francois, C. Gancedo, M.L. Giuseppin, J.J.
649 Heijnen, M. Hoare, H.C. Lange, E.A. Madden, P. Niederberger, J. Nielsen, J.L. Parrou, T. Petit, D.
650 Porro, M. Reuss, N. van Riel, M. Rizzi, H.Y. Steensma, C.T. Verrips, J. Vindelov, J.T. Pronk, An
651 interlaboratory comparison of physiological and genetic properties of four *Saccharomyces*
652 *cerevisiae* strains, *Enz. Microb. Techn.*, 26 (2000) 706-714.

653 [50] D.F. Steele, C.A. Butler, T.D. Fox, Expression of a recoded nuclear gene inserted into yeast
654 mitochondrial DNA is limited by mRNA-specific translational activation, *Proc. Natl. Acad. Sci.*
655 *U.S.A.*, 93 (1996) 5253-5257.

656

657 **Table 1. Genotypes and origins of yeast strains.**

Strain	Nuclear genotype	mtDNA	Source
MR6	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+	[48]
D273-10B/60	<i>Mata met6</i>	ρ^o	[49]
DFS160	<i>MATα leu2Δ ura3-52 ade2-101 arg8::URA3 kar1-1</i>	ρ^o	[50]
NB40-3C	<i>MATa lys2 leu2-3,112 ura3-52 his3ΔHindIII arg8::hisG</i>	ρ^+ <i>cox2-62</i>	[49]
MR10	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::hisG</i>	ρ^+ <i>atp6::ARG8^m</i>	[48]
RKY105	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-S₁₇₅N</i>	This study
RKY105-R1/3	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-I₁₇₁F+S₁₇₅N</i>	This study
RKY105-R1/4	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-I₂₃₉F+S₁₇₅N</i>	This study
RKY105-R2/3	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-I₂₀₀M+S₁₇₅N</i>	This study
RKY105-R2/5	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-P₁₂S+S₁₇₅N</i>	This study
RKY105-R6/5	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-S₁₇₅K</i>	This study
RKY105-R9/2	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ <i>atp6-S₁₇₅I</i>	This study

RKY105- R31/5	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ atp6-S ₁₇₅ D	This study
RKY105- R33/1	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ atp6-S ₁₇₅ T	This study
RKY105- R33/4	<i>MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arg8::HIS3</i>	ρ^+ atp6-I ₁₇₁ N+S ₁₇₅ N	This study

658

659

660

661
662

Table 2. Intragenic suppressors of the *atp6-S₁₇₅N* mutation.

Codon change	Amino acid change	Number
Original mutant		
TCT ₁₇₅ AAT	S ₁₇₅ N	-
Intragenic suppressors		
ATT ₁₇₁ TTT	I ₁₇₁ F	8
ATT ₁₇₁ AAT	I ₁₇₁ N	1
ATT ₂₃₉ TTT	I ₂₃₉ F	35
ATT ₂₀₀ ATA	I ₂₀₀ M	1
CCA ₁₂ TCA	P ₁₂ S	3
AAT ₁₇₅ GAT	N ₁₇₅ D	2
AAT ₁₇₅ AAA	N ₁₇₅ K	1
AAT ₁₇₅ ATT	N ₁₇₅ I	2
AAT ₁₇₅ ACT	N ₁₇₅ T	1
AAT ₁₇₅ AGT	N ₁₇₅ S	6

663

664
665

Table 3. Mitochondrial respiration ATP synthesis rates

Strain	Respiration rates nmol O ₂ .min ⁻¹ .mg ⁻¹				ATP synthesis rate nmol Pi.min ⁻¹ .mg ⁻¹		P/O	% ρ ⁻ /ρ ⁰
	NADH	NADH + ADP	NADH + CCCP	Asc/TMPD + CCCP	- oligo	+ oligo		
WT	410 ± 46	770 ± 40	1400 ± 195	2450 ± 283	828 ± 67	125 ± 21	1.08±0.03	<5%
S ₁₇₅ N	60 ± 5	60 ± 5	86 ± 5	1064 ± 620	82 ± 9	30 ± 10	1.37±0.04	<35%
S ₁₇₅ N+I ₂₀₀ M	263 ± 58	572 ± 89	763 ± 152	2163 ± 144	729 ± 139	198 ± 64	1.27±0.16	<2%
S ₁₇₅ N+I ₁₇₁ F	368 ± 81	781 ± 94	1422 ± 325	2886 ± 623	796 ± 26	429 ± 29	1.02±0.09	<3%
S ₁₇₅ N+I ₁₇₁ N	122 ± 36	181 ± 74	332 ± 163	1549 ± 284	131 ± 7	74 ± 4	0.72±0.26	<4%
S ₁₇₅ N+P ₁₂ S	254 ± 74	424 ± 97	910 ± 308	2603 ± 276	417 ± 34	146 ± 13	0.98±0.14	<6%
S ₁₇₅ N+I ₂₃₉ F	195 ± 51	330 ± 57	660 ± 107	1854 ± 213	347 ± 77	146 ± 30	1.05±0.05	<7%
S ₁₇₅ D	385 ± 87	674 ± 123	1206 ± 263	2567 ± 186	410 ± 20	197 ± 22	0.61±0.08	<12%
S ₁₇₅ K	303 ± 49	488 ± 93	745 ± 232	1861 ± 137	360 ± 9	118 ± 11	0.74±0.12	<4%
S ₁₇₅ I	340 ± 33	738 ± 13	1104 ± 90	2863 ± 142	934 ± 51	184 ± 9	1.27±0.05	<4%
S ₁₇₅ T	249 ± 62	693 ± 186	772 ± 95	2278 ± 224	965 ± 16	397 ± 28	1.39±0.35	<6%

666

667 Mitochondria were isolated from cells grown for 5-6 generations in rich galactose medium
668 (YPGalA) at 28°C. Reaction mixes for assays contained 0.15 mg/mL protein, 4 mM NADH,
669 150 (for respiration assays) or 750 (for ATP synthesis) μM ADP, 12.5 mM ascorbate (Asc),

670 1.4 mM N,N,N,N,-tetramethyl-p-phenylenediamine (*TMPD*), 4 μ M carbonyl cyanide-m-
671 chlorophenyl hydrazone (*CCCP*), 3 μ g/mL oligomycin (*oligo*). The values reported are
672 averages of triplicate assays \pm standard errors. The percentages of % ρ^-/ρ^0 in cultures are
673 indicated.

674

675

676

677